TECENTRIQ recall in Canada: Risk of immune-related myositis
In plain language
This recall involves TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials, sold in Canada. It's being recalled because it may cause immune-related myositis, a serious muscle inflammation. Patients should inform their healthcare professional if they experience symptoms.
What to do
- Inform your healthcare professional if you are receiving TECENTRIQ and experience muscle weakness, muscle pain, or difficulty moving, breathing, or swallowing.
- Contact your healthcare professional for more information on this safety update.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials
Why this matters
Risk of immune-related myositis
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of immune-related myositis
What should consumers do?
Inform your healthcare professional if you are receiving TECENTRIQ and experience muscle weakness, muscle pain, or difficulty moving, breathing, or swallowing. Contact your healthcare professional for more information on this safety update.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of immune-related myositis
When was this product recalled?
This product was recalled on March 13, 2019.
Is the TECENTRIQ brand affected by this recall?
Yes, TECENTRIQ products are affected by this recall. This recall involves TECENTRIQ (atezolizumab) concentrate for solution for infusion, 60 mg / mL in 20 mL single use vials, sold in Canada. It's being recalled because it may cause immune-related myositis, a serious muscle inflammation. Patients should inform their healthcare professional if they experience symptoms.